Alembic Pharma Q1 net profit jumps over two-folds to Rs 301.46 crore

Alembic Pharmaceuticals

Drug firm Alembic Pharmaceuticals on Wednesday reported more than two-fold jump in consolidated net profit to Rs 301.46 crore for the quarter ended on June 30, 2020, mainly on account of robust sales in international markets.

The company had posted a net profit of Rs 123.72 crore for the corresponding period of the previous fiscal, Alembic Pharmaceuticals said in a filing to BSE.

Consolidated revenue from operations of the company stood at Rs 1,341.32 crore for the period under consideration against Rs 948.91 crore for the same period year ago, it added.

"It was an excellent quarter for the company backed by growth in all the international markets. Despite exceptionally, challenging circumstances, the operating teams ensured profitability and growth," Alembic Pharmaceuticals MD Pranav Amin said.

International formulations revenue grew 70 per cent to Rs 771 crore in the quarter, the company said.

Shares of Alembic Pharmaceuticals were trading at Rs 1,010.15 on BSE, up 1.55 per cent from the previous close.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel